الفهرس 
Polycystic Ovary SyndromeOnly 14 pages are availabe for public view
 |  | from | 206 |  |  |
| | | from | 206 | | |
Abstract
Background: : Ovarian hyperstimulation syndrome (OHSS) is a risk associated with assisted reproductive technology. There is a link between higher incidences of OHSS and higher blood estrogen levels. With its strong, targeted, and reversible inhibition of aromatase and E synthetase, the nonsteroidal aromatase inhibitor letrozole can prevent the conversion of androgens into estrogens.
Methods: Study populations were divided into two equal groups: group I: Consisted of 85 women who received controlled ovarian stimulation with a conventional antagonist protocol and letrozole. group II: Consisted of 85 women who received controlled ovarian stimulation with a conventional GnRH antagonist protocol and a placebo.
Results:There were statistically significant differences among the groups in terms of Estradiol level on Trigger Day (p= 0.037),Number of oocytes retrieved (p=0.018). The total days of stimulation and cumulative Gonadotropin dose were significantly lower in the Letrozole group (p= 0.045). There were no significant differences between the groups as regard endometrial thickness at trigger day, number of fertilized oocytes, fertilization rate, embryos transferred per cycle, and fresh embryos transferred , mild and critical early onset OHSS, Cycle cancels, Biochemical pregnancy, and Clinical pregnancy between the two groups (P>0.05).There was a significant difference as regard moderate and severe early onset OHSS between the two groups (P<0.05).
Conclusion:We’ve concluded that for PCOS patients facing a high risk of OHSS, supplementing the GnRH-ant protocol with LE offers a safer, more effective, cost-efficient, and patient-friendly approach compared to the traditional GnRH-ant protocol. The use of LE alongside conventional protocols might alleviate severe forms of OHSS, even among those at extreme risk, without compromising the potential for implantation, pregnancy, and delivery